FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229007910> ?p ?o ?g. }

• W4229007910 abstract "Abstract BACKGROUND AND AIMS Idiopathic membranous nephropathy (IMN) is one of the main causes of nephrotic syndrome in the adult population. Approximately between 20% and 40% of patients who suffer from it require replacement therapy in a period of 10–15 years. Recently, it has been reported that antibodies against the Type M phospholipase A2 receptor (APLA2R) are responsible for between 69% and 82% of cases with IMN in different parts of the world. Until now, the diagnosis and clinical follow-up of IMN requires the performance of a renal biopsy and proteinuria measurements. METHOD Diagnostic test study in a cohort of 106 patients who continued to be followed up in the nephrology outpatient clinic (EC), in the period from 1 January 2009 to 31 January 2017. Serum samples were taken and analyzed of patients with histological diagnosis of IMN with proteinuria &gt; and &lt;1 g in 24 h and other glomerular diseases other than IMN such as lupus nephritis, diabetic nephropathy, primary glomerular diseases and kidney donors (healthy subjects) with measurement of APLA2R by ELISA (EUROIMMUN ) concomitant with measurement of 24-h urine proteinuria. RESULTS In 22 of 106 patients, an APLA2R concentration &gt;9 RU/mL was found and all these cases had IMN (21 active IMN, Proteinuria &gt;1 g in 24 h and 1 inactive IMN, Proteinuria &lt; 1 g in 24 h). The prevalence of seropositivity in cases with active IMN was 78% (21/27). APLA2R concentrations were positively correlated with 24-h urine proteinuria (r = .68) and serum cholesterol (r = .42) and negative with serum albumin (r = −0.34). All these correlations were statistically significant with a P &lt; .001. The area under the ROC curve (AB-ROC) of APLA2R was 0.87 (95% CI 78–0.96). When comparing subjects with active IMN versus other subjects with glomerular diseases, with a cut-off point of 9 RU/mL, the sensitivity was 78% and the specificity 99%. CONCLUSION The APLA2Rs have an adequate diagnostic utility to diagnose IMN in the selected population; especially in subjects with proteinuria greater than 1 g/day, with a sensitivity of 78% with a specificity of 99%. The APLA2Rs are useful for the diagnosis of idiopathic membranous nephropathy, especially when there is proteinuria greater than 1 g in 24 h. The APLA2Rs measured by ELISA with titers greater than 9 RU/mL exclude other glomerular diseases and are highly specific for the diagnosis of IMN, which could prevent the performance of a renal biopsy." @default.
• W4229007910 created "2022-05-08" @default.
• W4229007910 creator A5048759698 @default.
• W4229007910 date "2022-05-01" @default.
• W4229007910 modified "2023-09-27" @default.
• W4229007910 title "MO210: Anti-Receptor Type M Antibodies of Phospholipase A2 in the Diagnosis of Primary Membrane Nephropathy" @default.
• W4229007910 doi "https://doi.org/10.1093/ndt/gfac067.009" @default.
• W4229007910 hasPublicationYear "2022" @default.
• W4229007910 type Work @default.
• W4229007910 citedByCount "0" @default.
• W4229007910 crossrefType "journal-article" @default.
• W4229007910 hasAuthorship W4229007910A5048759698 @default.
• W4229007910 hasConcept C126322002 @default.
• W4229007910 hasConcept C126894567 @default.
• W4229007910 hasConcept C159641895 @default.
• W4229007910 hasConcept C2775946357 @default.
• W4229007910 hasConcept C2778930706 @default.
• W4229007910 hasConcept C2779134260 @default.
• W4229007910 hasConcept C2779561371 @default.
• W4229007910 hasConcept C2779912601 @default.
• W4229007910 hasConcept C2780026642 @default.
• W4229007910 hasConcept C2780091579 @default.
• W4229007910 hasConcept C2781087799 @default.
• W4229007910 hasConcept C2908647359 @default.
• W4229007910 hasConcept C54847362 @default.
• W4229007910 hasConcept C71924100 @default.
• W4229007910 hasConcept C90924648 @default.
• W4229007910 hasConcept C99454951 @default.
• W4229007910 hasConceptScore W4229007910C126322002 @default.
• W4229007910 hasConceptScore W4229007910C126894567 @default.
• W4229007910 hasConceptScore W4229007910C159641895 @default.
• W4229007910 hasConceptScore W4229007910C2775946357 @default.
• W4229007910 hasConceptScore W4229007910C2778930706 @default.
• W4229007910 hasConceptScore W4229007910C2779134260 @default.
• W4229007910 hasConceptScore W4229007910C2779561371 @default.
• W4229007910 hasConceptScore W4229007910C2779912601 @default.
• W4229007910 hasConceptScore W4229007910C2780026642 @default.
• W4229007910 hasConceptScore W4229007910C2780091579 @default.
• W4229007910 hasConceptScore W4229007910C2781087799 @default.
• W4229007910 hasConceptScore W4229007910C2908647359 @default.
• W4229007910 hasConceptScore W4229007910C54847362 @default.
• W4229007910 hasConceptScore W4229007910C71924100 @default.
• W4229007910 hasConceptScore W4229007910C90924648 @default.
• W4229007910 hasConceptScore W4229007910C99454951 @default.
• W4229007910 hasIssue "Supplement_3" @default.
• W4229007910 hasLocation W42290079101 @default.
• W4229007910 hasOpenAccess W4229007910 @default.
• W4229007910 hasPrimaryLocation W42290079101 @default.
• W4229007910 hasRelatedWork W1903400040 @default.
• W4229007910 hasRelatedWork W2037929726 @default.
• W4229007910 hasRelatedWork W2380303909 @default.
• W4229007910 hasRelatedWork W2560171887 @default.
• W4229007910 hasRelatedWork W3022896292 @default.
• W4229007910 hasRelatedWork W3028362203 @default.
• W4229007910 hasRelatedWork W4229038821 @default.
• W4229007910 hasRelatedWork W4283792760 @default.
• W4229007910 hasRelatedWork W4296373815 @default.
• W4229007910 hasRelatedWork W90396326 @default.
• W4229007910 hasVolume "37" @default.
• W4229007910 isParatext "false" @default.
• W4229007910 isRetracted "false" @default.
• W4229007910 workType "article" @default.